The original STEP 1 trial randomized 1,961 adults with obesity to receive either semaglutide 2.4 mg or placebo for 68 weeks alongside lifestyle intervention
With the 3.0 mL reconstitution, you have drawn 2.10 mL of your 3.0 mL solution, leaving 0.90 mL
Combined with proper medication storage and handling, genetic insight ensures you're receiving truly individualized treatment
Furthermore, the cardiovascular disease prevention criteria resulted in the qualification of around 8.9 million adults aged 45 and older who met the eligibility criteria due to a high BMI and a history of major cardiovascular events, such as myocardial infarction or stroke
Overgaard RV, Petri KC, Jacobsen LV, Jensen CB
At Glow Savannah, we believe in offering holistic solutions that empower you to achieve your health and wellness goals